Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXYBOND vs DAYPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Osteoarthritis,Rheumatoid arthritis
Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.
600 mg orally once daily; max 1200 mg/day
3.5–6 hours; prolonged in renal impairment, hepatic impairment, or elderly patients, requiring dose adjustment.
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Primarily hepatic via CYP3A4 and to a lesser extent CYP2D6. Oxycodone is metabolized to noroxycodone (via CYP3A4), oxymorphone (via CYP2D6), and other minor metabolites.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Primarily renal (90% as free drug and glucuronide conjugates). Fecal elimination accounts for <10%.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
Approximately 20–30%, primarily to albumin.
>99% bound primarily to albumin.
2.6–4.0 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, liver).
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Oral: 10–20% (extensive first-pass metabolism); intranasal: 30–50%; intravenous: 100%.
Oral: approximately 80-90%.
For GFR 30-59 m L/min: reduce dose by 25% and increase dosing interval. For GFR <30 m L/min: reduce dose by 50% and administer every 12 hours. Avoid in ESRD.
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and increase interval. Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
Weight-based dosing: 0.1-0.2 mg/kg/dose every 4-6 hours as needed. Maximum single dose: 5 mg for <50 kg, 10 mg for ≥50 kg.
Not approved for pediatric use
Start at lowest effective dose (2.5-5 mg every 4-6 hours). Titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor renal function.
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression; Accidental Ingestion; Neonatal Opioid Withdrawal Syndrome; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants; and Risk of Medication Errors (due to immediate-release formulation, which requires careful dose conversion from other oxycodone products).
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Life-threatening respiratory depression, especially in elderly, cachectic, or debilitated patients and those with pre-existing respiratory conditions.,Risk of opioid-induced hyperalgesia.,Adrenal insufficiency with prolonged use.,Severe hypotension, including orthostatic hypotension, in patients with compromised ability to maintain blood pressure.,Risk of serotonin syndrome with concomitant serotonergic drugs.,Seizures in patients with seizure disorders or taking other seizure threshold-lowering drugs.,Avoid abrupt discontinuation; taper dose to prevent withdrawal syndrome.
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to oxycodone or any component of the formulation
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
Avoid alcohol and any alcohol-containing foods or beverages. Grapefruit and grapefruit juice may increase oxycodone levels; avoid concurrent use.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Avoid during labor due to respiratory depression in the newborn.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Small amounts of oxycodone are excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 3:1. Use with caution, especially in mothers who are ultrarapid metabolizers of CYP2D6, as this increases risk of toxicity in the infant. Monitor infant for drowsiness, poor feeding, and respiratory depression.
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
Pregnancy may increase oxycodone clearance due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed: consider increasing the frequency or dose based on pain control and tolerance. Avoid high doses near term; use lowest effective dose. Monitor for respiratory depression in both mother and neonate.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
ROXYBOND (oxycodone hydrochloride) is an immediate-release opioid agonist indicated for acute pain severe enough to require an opioid. Its unique formulation resists crushing and dissolution, but it can still be abused intravenously. Be aware of the risk of respiratory depression, particularly in opioid-naive patients. Use with caution in patients with respiratory disease, or in elderly or debilitated patients. Tolerance and dependence can develop; monitor for signs of misuse. Naloxone is the reversal agent. Not indicated for as-needed use; prescribe the lowest effective dose for the shortest possible duration.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
Take exactly as prescribed; do not break, crush, chew, or dissolve the tablet as it can cause rapid release and fatal overdose.,Do not consume alcohol or any alcohol-containing products while taking ROXYBOND.,Store securely out of sight and reach of children and pets; properly dispose of unused tablets via a drug take-back program.,Side effects include constipation, nausea, dizziness, and drowsiness; contact your healthcare provider if you experience difficulty breathing or extreme sleepiness.,Avoid driving or operating heavy machinery until you know how ROXYBOND affects you.,Do not share this medication with others; it can cause addiction and death.,Inform your doctor about all other medications, especially sedatives, tranquilizers, or antidepressants.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXYBOND vs DAYPRO, answered by our medical review team.
ROXYBOND is a Opioid Analgesic that works by ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.. DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXYBOND and DAYPRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXYBOND is: Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.. The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXYBOND and DAYPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXYBOND is classified as Category C. ROXYBOND (oxycodone) is an opioid agonist. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Chr. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.